Uni-Bio Science Group Limited — M&A Activity 2007

Jul 26, 2007

==> picture [305 x 58] intentionally omitted <==

==> picture [7 x 6] intentionally omitted <==

----- Start of picture text ----- *----- End of picture text -----

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 690)

ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09 of the Listing Rules.

Reference is made to the announcement of the Company dated 24 July 2007 regarding the proposed acquisition of the entire equity interest in Zethanel.

This announcement is made pursuant to Rule 13.09 of the Listing Rules.

Reference is made to the announcement of the Company dated 24 July 2007 (the “ Announcement ”) relating to the proposed acquisition of the entire equity interest in Zethanel. Terms used in this announcement have the same meanings as defined in the Announcement.

The Company wishes to provide additional information on the Target Group. As disclosed in the Announcement, Shenzhen Watsin (the operating subsidiary of the Target Group) is principally engaged in the development, manufacturing and marketing of bio-pharmaceutical products. Its main products are recombinant human epidermal growth factor products (“ EGF products ”) in liquid preparations primarily indicated for external use for burn and wound care. The flagship product, “GENETIME”, is a liquid spray EGF formulation and has been granted a Class I prescription new drug certificate by the Ministry of Health of the PRC. The Group is currently the exclusive distributor of EGF products for Shenzhen Watsin in the PRC.

In July 2007, Shenzhen Watsin obtained the approval to distribute and sell its flagship EGF product “GENETIME” in the Russian Federation and have already succeeded in making sales of such EGF product “GENETIME” in the Russian Federation following the grant of such approval.

The Russian Federation have a population of approximately 142.9 million and an estimated GDP of about USD 733 billion in 2006 according to the U.S. State Department. The pharmaceutical and healthcare industries are enjoying strong support from governments around the world including those of the PRC and the Russian Federation. The Board is optimistic that the Acquisition, if materialized, could consolidate further the market position of the Group in the bio-science and pharmaceutical industries in the PRC and help pave the way for the Group’s expansion overseas.

1

A circular containing additional information on the Target Group will be despatched to Shareholders in accordance with the Listing Rules as soon as practicable.

By Order of the Board Uni-Bio Science Group Limited Tong Kit Shing Chairman

Hong Kong, 26 July 2007

* For identification purposes only

As at the date of this announcement, the executive Directors are Mr. Tong Kit Shing (Chairman), Mr. Liu Guoyao and Mr. Cheng Wai Man; the independent non-executive Directors are Mr. Zhou Yaoming, Mr. Lin Jian and Mr. So Yin Wai.

2